| Identification | Back Directory | [Name]
THZ1 | [CAS]
1604810-83-4 | [Synonyms]
THZ1
CS-1233
CDK7 inhibitor
THZ1 free base
THZ1, CDK7 inhibitor
THZ-1;THZ 1;CDK7 INHIBITOR
CDK7 INHIBITOR; THZ-1; THZ 1
THZ1 HY-80013 GTPL8052 SCHEMBL14979765
(E)-N-(3-((5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)-4-(4-(dimethylamino)but-2-en
(E)-N-(3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)-4-(4-(dimethylamino)but-2-enamido)benzamide
THZ1 ?N-{4-[5-Chloro-4-(1H-indol-3-yl)-pyrimidin-2-ylamino]-phenyl}-4-(4-dimethylamino-but-2-enoylamino)-benzamide
(E)-N-(3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)-4-(4-(dimethylamino)but-2-enamido)benzamide THZ1
(E)-N-(3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)-4-(4-(dimethylamino)but-2-enamido)benzamide hydrochloride
N-[3-[[5-Chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-4-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]benzamide
Benzamide, N-[3-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-4-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]- | [Molecular Formula]
C31H28ClN7O2 | [MDL Number]
MFCD28167785 | [MOL File]
1604810-83-4.mol | [Molecular Weight]
566.05 |
| Chemical Properties | Back Directory | [density ]
1.379±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
≥28.3 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH | [form ]
Powder | [pka]
12.94±0.70(Predicted) | [color ]
Off-white to yellow | [InChIKey]
OBJNFLYHUXWUPF-IZZDOVSWSA-N | [SMILES]
C(NC1=CC=CC(NC2=NC=C(Cl)C(C3C4=C(NC=3)C=CC=C4)=N2)=C1)(=O)C1=CC=C(NC(=O)/C=C/CN(C)C)C=C1 |
| Hazard Information | Back Directory | [Uses]
THZ1 is a covalent cyclin-dependent kinases 7 (CDK7) inhibitor. It has the ability to target a remote cysteine residue located outside of the canonical kinase domain, providing a means of achieving selectivity for CDK7. | [Biological Activity]
thz1 is a covalent inhibitor of cdk7 with ic50 value of 3.2nm [1].thz1 covalently modifies cdk7 by targeting c312 residue outside of the kinase domain, providing an unanticipated means of achieving covalent selectivity. thz1 potently inhibits proliferation of jurkat and loucy t-all cell lines with ic50 values of 50nm and 0.55nm, respectively. in the kinase binding assay, thz1 shows a good binding affinity with ic50 value of 3.2nm [1].as an inhibitor of cdk7, thz1 inhibits the phosphorylation of the c-terminal domain of rnap polymerase ii, effecting the regulation of transcription. thz1 also inhibits the activation of the cdk proteins. it is reported to disrupt the cdk7 signalling pathways both in jurkat cells and loucy cells. thz1 shows a broad-based activity with ic50 values less than 200nm in a variety of cancer cell lines. among these cell lines, t-all is exceptional sensitivity to thz1 due to the transcription effect of runx1 caused by thz1 [1]. | [in vivo]
THZ1 (10 mg/kg) demonstrates potent killing of primary chronic lymphocytic leukemia (CLL) cells and anti-proliferative activity against primary TALL cells and in vivo against a human T-ALL xenograft[1].
THZ1 (10 mg/kg, i.v.) inhibits tumor growth in a mouse model of human MYCN-amplified NB and shows no toxicity[4].
THZ1 (10 mg/kg, i.p.) completely suppresses oesophageal squamous cell carcinoma tumour growth in vivo without loss of body weight or other common toxic effects[5]. | [target]
CDK7 | [IC 50]
CDK7: 3.2 nM (IC50); CDK12; CDK13 | [storage]
Store at -20°C | [References]
[1] nicholas kwiatkowski, tinghu zhang, peter b. rahl et al. targeting transcription regulation in cancer with a covalent cdk7 inhibitor. nature, 2014. |
|
| Company Name: |
Spectrum Chemical Manufacturing Corp.
|
| Telephone: |
021-021-021-67601398-809-809-809 15221380277 |
| Website: |
www.spectrumchemical.com/oa_html/index.jsp?minisite=10020&respid=22372&language=us |
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
|